Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274287 · ClinicalTrials.gov registry record · Phase 2
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00274287: Completed Phase 2 study, sponsored by Oncology Specialists, S.C..
NCT00274287 is a Phase 2 study that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00274287, a Phase 2 study, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.
Primary Outcome
The primary end point of this study is to evaluate time to disease progression (TTP). TTP is defined as the time from starting taxotere until there is evidence of progressive disease (PD) as defined below (radiographically and/or biochemically). PD was defined as more than 20% in the sum of longest diameter of measurable lesions compared to baseline, and/or evidence of new lesions on imaging studies. Median TTP from GM-CSF administration and Median TTP from start of chemotherapy is being reporte
Interventions
- DRUG GM CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00274287 record still lists
NCT00274287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which GM CSF is the first listed.
NCT00274287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00274287 about?
NCT00274287 is a clinical study titled "GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere". This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other chemotherapy schedule.
What is the current status of trial NCT00274287?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00274287?
The interventions under investigation include: GM CSF (DRUG).
Who is sponsoring clinical trial NCT00274287?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00274287's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia